Saturday 17 October 2026 Export SRPT’s income statement to Excel — free account

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

17.06 0.73 −4.10%

Follow SRPT

Alert me

Market cap: $1.9B
P/E: 0.0×
Fwd P/E: 4.4×
Dividend yield: —
F-score: 3/9
Altman Z: −0.97
Beneish M: −3.41
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.42

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	1	—	—	—	—	—	—	—

Insider Ownership 4.73%

Capital & Financial Ratios $m

Market Cap 1,880.00

Revenue 1,974.34

Net Income (136.72)

Free Cash Flow 74.97

Net Debt 59.13

Current Ratio 4.42

Debt/Equity 0.55

P/E ratio 0.00

Fwd P/E 4.44

P/S ratio 0.91

P/B ratio 1.18

Past 5Y EPS Growth —

This Y EPS Growth 143.98%

Next Y EPS Growth (83.81%)

Next Y revenue growth (16.57%)

Next 5Y EPS Growth 5.64%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 7.04%

10-year low 10-year high

P/B against its own 10 years 1.70%

10-year low 10-year high

EV/Sales against its own 10 years 6.78%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,676	1,355	940	788
Receivables	400	602	398	377
Inventory	323	750	915	904
Other	180	367	285	154
	2,579	3,073	2,538	2,224

	2023	2024	2025	Q'26
Payables	165	214	281	51
ST’ Debt	105	—	—	—
Other	18	13	11	17
	654	732	1,095	503

Compound Annual Growth %

	10y	5y	3y
Sales	111.06%	32.41%	33.06%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	19.61%	8.41%	43.63%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	731	401	—	—	—
’25	745	611	399	443	2,198
’24	413	363	467	658	1,902
’23	254	261	332	397	1,243
’22	211	233	230	258	933
’21	147	164	189	201	702
’20	114	137	144	145	540

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(203)	197	—	—	—
’25	(583)	261	(15)	131	(205)
’24	(242)	15	(71)	92	(206)
’23	(209)	(122)	(115)	(55)	(501)
’22	(101)	(67)	(65)	(92)	(325)
’21	(180)	(109)	(124)	(29)	(443)
’20	628	(108)	(238)	(175)	107

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(206)	197	—	—	—
’25	(629)	230	(43)	127	(315)
’24	(285)	(14)	(108)	54	(353)
’23	(219)	(38)	(155)	(74)	(486)
’22	(107)	(76)	(74)	(101)	(358)
’21	(202)	(13)	(134)	(34)	(382)
’20	727	(127)	(263)	(203)	133

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	2.88	(0.05)	—	—	—
’25	(4.60)	1.89	(1.80)	(2.58)	(7.13)
’24	0.37	0.07	0.34	1.50	2.34
’23	(5.86)	(0.27)	(0.46)	0.47	(5.80)
’22	(1.20)	(2.65)	(2.94)	(1.24)	(8.03)
’21	(2.10)	(1.02)	(0.60)	(1.42)	(5.15)
’20	(0.23)	(1.93)	(2.50)	(2.40)	(7.11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8.00	26.26	50.68	72.05	78.06	65.30	61.28	55.25	91.34	10.42	Analyst estimates 2026–2028 Powerpack
	High	63.73	57.57	176.50	158.80	181.83	174.49	134.08	159.89	173.25	129.84
People
People	Employees	197	255	499	743	866	840	1,162	1,314	1,372	835
	Revenue/emp, $m	0.03	0.61	0.60	0.51	0.62	0.84	0.80	0.95	1.39	2.63
Income, $m
Income, $m	Revenue	5	155	301	381	540	702	933	1,243	1,902	2,198
	Gross margin, %	98.14	95.24	88.64	85.14	88.26	86.17	85.00	87.91	83.22	61.81
	EBT	(267)	(49)	(363)	(714)	(553)	(419)	(690)	(520)	261	(702)
	EBT margin, %	(4,930.18)	(31.46)	(120.45)	(187.45)	(102.40)	(59.69)	(73.95)	(41.83)	13.71	(31.94)
	Net income	(267)	(51)	(362)	(715)	(554)	(419)	(703)	(536)	235	(713)
	Depreciation	6	7	5	25	27	38	31	(2)	(3)	39
Per share, $
Per share, $	Revenue	0.11	2.63	4.54	5.17	6.93	8.64	10.66	13.46	20.01	21.96
	Earnings	(5.49)	(0.86)	(5.46)	(9.71)	(7.11)	(5.15)	(8.03)	(5.80)	2.47	(7.13)
	Cash flow	(5.05)	(3.94)	(5.87)	(6.20)	1.38	(5.45)	(3.72)	(5.42)	(2.16)	(2.05)
	Capex	(0.14)	1.76	(0.92)	(0.81)	0.33	0.75	(0.37)	0.16	(1.55)	(1.10)
	Free cash flow	(5.19)	(2.18)	(6.79)	(7.01)	1.71	(4.70)	(4.08)	(5.26)	(3.71)	(3.15)
	Book value	6.91	13.42	15.58	11.11	9.77	11.42	4.40	9.30	16.07	11.39
	Shares, m	49	59	66	74	78	81	88	92	95	100
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	49.63	0.00
	P/S	139.35	22.16	24.02	24.94	24.61	10.43	11.72	7.15	6.08	0.98
	P/B	4.04	4.34	7.00	11.61	17.45	7.89	28.40	10.34	7.57	1.89
	EV/Sales	107.33	17.97	21.55	23.80	22.90	9.00	11.25	6.80	6.01	0.97
	EV/FCF	(4.14)	(21.67)	(14.32)	(17.45)	92.74	(16.53)	(29.18)	(17.38)	(32.41)	(6.77)
Cash, $m
Cash, $m	Operating cash flow	(246)	(232)	(389)	(456)	107	(443)	(325)	(501)	(206)	(205)
	Capex	(7)	104	(61)	(60)	26	61	(32)	15	(147)	(110)
	Free cash flow	(253)	(128)	(450)	(516)	133	(382)	(358)	(486)	(353)	(315)
Balance, $m
Balance, $m	Working capital	298	1,140	1,252	1,204	2,069	2,151	1,938	1,926	2,342	1,443
	Total debt	16	431	421	690	1,013	1,112	1,559	1,238	1,137	829
	Net debt	(312)	(648)	(753)	(435)	(925)	(1,004)	(430)	(438)	(218)	(111)
	Shareholders’ equity	337	789	1,032	818	762	928	385	859	1,528	1,141
Returns, %
Returns, %	ROA	(76.59)	(5.85)	(24.54)	(41.28)	(23.05)	(13.66)	(22.42)	(16.77)	6.51	(19.51)
	ROIC	(686.01)	(75.97)	(77.00)	(115.04)	0.00	0.00	0.00	(39.75)	10.40	(42.46)
	ROE	(101.42)	(9.00)	(39.74)	(77.29)	(70.15)	(49.57)	(107.16)	(86.15)	19.71	(53.47)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LKFT Lakefront Biotherapeutics - Sponsored ADR	$2.0B	— (loss-making)	— (loss-making)	−95.35% (below 0%: shrinking)	+198.85% (above 0%: growing)	+18.22% (above 0%: growing)	25.95%	(982.91%)	Compare
AGIO Agios Pharmaceuticals, Inc.	$1.9B	— (loss-making)	— (loss-making)	+259.25% (above 0%: growing)	n/m	+24.97% (above 0%: growing)	93.30%	(247.07%)	Compare
MLYS Mineralys Therapeutics, Inc.	$1.9B	— (loss-making)	—	—	n/m	−7.91% (below 0%: shrinking)	—	0.00%	Compare
SRPT Sarepta Therapeutics, Inc.	$1.9B	— (loss-making)	4.4×	−34.34% (below 0%: shrinking)	n/m	−14.48% (below 0%: shrinking)	62.77%	3.31%
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)	Compare
ZYME Zymeworks Inc.	$1.8B	— (loss-making)	16.2×	−90.58% (below 0%: shrinking)	n/m	−385.53% (below 0%: shrinking)	(497.71%)	(918.95%)	Compare
PVLA Palvella Therapeutics, Inc.	$1.8B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)	Compare
URGN Urogen Pharma	$1.8B	— (loss-making)	— (loss-making)	+199.22% (above 0%: growing)	n/m	+17.26% (above 0%: growing)	90.93%	0.15%	Compare
Median of peers	$1.8B	—	—	−13.41%	—	+4.68%	40.14%	(138.20%)

All 614 Biotechnology stocks →

Sarepta Therapeutics, Inc. (SRPT) key facts

Strength: Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
Sarepta Therapeutics, Inc. (SRPT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SRPT traded at $17.06, a market capitalization of $1.9 billion.
Return on equity was −53.5% and debt-to-equity 0.55.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.97 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.